Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $21.11M
• Dividend Yield: N/A
• Average Volume (3M): 314.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: -18.05%
• EPS Growth: 33.87%
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.93
• Shares Outstanding: 9,911,913
• 10 Day Avg. Volume: 289,104
• 30 Day Avg. Volume: 314,725
• PEG Ratio: 0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -6.32
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 0.15
• Enterprise Value/Ebitda: 1.32
• 1Y Price Target: $9.17
• Price Target Upside: 351.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $2.00 ▼(-1.48% Downside)

Aytu BioScience's overall score reflects significant financial challenges and a cautious valuation. However, the upcoming ExuA launch and positive adjusted EBITDA provide some optimism. Technical indicators suggest potential downward pressure, warranting careful monitoring.

Positive Factors

ExuA Launch

The launch of ExuA, targeting a $22 billion market, could significantly enhance Aytu's market position and address unmet needs in MDD treatment.

Positive Adjusted EBITDA

Consistent positive adjusted EBITDA reflects operational efficiency and financial discipline, supporting long-term business sustainability.

Pediatric Portfolio Growth

Growth in the pediatric portfolio indicates successful execution of growth strategies and potential for further market expansion.

Negative Factors

Decline in Gross Margin

A declining gross margin can pressure profitability, highlighting the need for cost management and operational efficiency improvements.

ADHD Portfolio Stability Concerns

Flat revenue and potential generic competition in the ADHD portfolio could limit growth and impact competitive positioning.

Impairment Expense Impact

Impairment expenses indicate asset write-downs, impacting financial health and signaling potential strategic shifts or challenges.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

How the Company Makes Money

Aytu BioScience generates revenue through the sale of its pharmaceutical products and diagnostic tests. The company has a diversified revenue model that includes direct sales of its proprietary products, as well as partnerships with other pharmaceutical companies for co-promotion and distribution. Key revenue streams are derived from product sales in the urology and pediatric markets, where Aytu has established a presence. Additionally, the company may benefit from licensing agreements, collaborations, and research grants that contribute to its financial performance. Strategic partnerships with healthcare providers and institutions also play a crucial role in expanding its market reach and enhancing sales.

Aytu BioScience Financial Statement Overview

Summary

Aytu BioScience faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin, the negative net profit margin and cash flow issues highlight the need for strategic improvements.

Income Statement

Aytu BioScience's income statement reveals challenges with profitability and revenue growth. The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of -4.10%. Gross profit margin remains relatively strong at 69.04%, indicating efficient production, but the net profit margin is negative at -20.43%, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.10, suggesting manageable leverage. However, the return on equity is significantly negative at -71.51%, indicating poor returns for shareholders. The equity ratio stands at 15.27%, showing a reasonable proportion of equity financing relative to total assets.

Cash Flow

Cash flow analysis indicates a concerning decline in free cash flow growth at -62.28%. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.12, suggesting that free cash flow covers net losses, albeit with limited margin.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.38M	66.38M	81.00M	107.40M	96.67M	65.63M
Gross Profit	45.83M	45.83M	49.37M	66.63M	46.44M	29.20M
EBITDA	5.13M	-4.67M	-1.01M	-3.27M	-98.74M	-29.04M
Net Income	-13.56M	-13.56M	-15.84M	-17.05M	-108.78M	-58.29M
Balance Sheet
Total Assets	124.43M	124.18M	118.09M	136.46M	137.62M	265.67M
Cash, Cash Equivalents and Short-Term Investments	30.95M	30.95M	20.01M	22.98M	19.36M	49.65M
Total Debt	22.94M	1.86M	16.42M	18.45M	18.19M	28.35M
Total Liabilities	105.46M	105.21M	90.38M	97.11M	93.31M	128.10M
Stockholders Equity	18.97M	18.97M	27.72M	39.36M	44.31M	137.57M
Cash Flow
Free Cash Flow	-5.17M	-2.17M	-1.39M	-5.13M	-28.82M	-28.30M
Operating Cash Flow	-1.94M	-1.94M	-1.39M	-5.13M	-28.82M	-25.96M
Investing Cash Flow	-2.56M	-2.56M	-329.00K	-117.00K	-3.25M	-2.78M
Financing Cash Flow	15.44M	15.44M	-1.26M	8.87M	1.53M	30.31M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Negative. The current price of 2.03 is below the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.23, and above the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.74 is Neutral, neither overbought nor oversold. The STOCH value of 46.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$21.11M	-0.76	-60.76%	―	-18.05%	33.87%
TXMD	47 Neutral	$13.54M	-29.32	-1.98%	―	156.93%	92.75%
COSM	41 Neutral	$20.93M	-0.68	-52.69%	―	―	―
FLGC	38 Underperform	$6.77M	-0.23	-230.73%	―	-22.60%	53.82%

Aytu BioScience Corporate Events

Aytu BioPharma’s Optimistic Earnings Call Highlights ExuA Launch

Aytu BioPharma’s recent earnings call was marked by a sense of optimism and strategic focus. The company expressed significant enthusiasm about the upcoming launch of ExuA, a novel treatment for major depressive disorder, and celebrated its third consecutive year of positive adjusted EBITDA. However, the call also acknowledged challenges such as a decline in gross margin and potential competition in the ADHD portfolio, which could pose hurdles moving forward.

Aytu BioPharma Reports Fiscal 2025 Earnings and EXXUA Launch Plans

Aytu BioPharma, Inc. is a pharmaceutical company dedicated to developing innovative treatments for complex central nervous system diseases, with a focus on improving patient quality of life. The company offers prescription products for conditions such as major depressive disorder and ADHD.